Correlation Between ArriVent BioPharma, and ScanTech

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both ArriVent BioPharma, and ScanTech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining ArriVent BioPharma, and ScanTech into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between ArriVent BioPharma, Common and ScanTech AI Systems, you can compare the effects of market volatilities on ArriVent BioPharma, and ScanTech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in ArriVent BioPharma, with a short position of ScanTech. Check out your portfolio center. Please also check ongoing floating volatility patterns of ArriVent BioPharma, and ScanTech.

Diversification Opportunities for ArriVent BioPharma, and ScanTech

0.66
  Correlation Coefficient

Poor diversification

The 3 months correlation between ArriVent and ScanTech is 0.66. Overlapping area represents the amount of risk that can be diversified away by holding ArriVent BioPharma, Common and ScanTech AI Systems in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ScanTech AI Systems and ArriVent BioPharma, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on ArriVent BioPharma, Common are associated (or correlated) with ScanTech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ScanTech AI Systems has no effect on the direction of ArriVent BioPharma, i.e., ArriVent BioPharma, and ScanTech go up and down completely randomly.

Pair Corralation between ArriVent BioPharma, and ScanTech

Given the investment horizon of 90 days ArriVent BioPharma, Common is expected to generate 0.25 times more return on investment than ScanTech. However, ArriVent BioPharma, Common is 3.95 times less risky than ScanTech. It trades about -0.08 of its potential returns per unit of risk. ScanTech AI Systems is currently generating about -0.05 per unit of risk. If you would invest  2,360  in ArriVent BioPharma, Common on June 8, 2025 and sell it today you would lose (408.00) from holding ArriVent BioPharma, Common or give up 17.29% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

ArriVent BioPharma, Common  vs.  ScanTech AI Systems

 Performance 
       Timeline  
ArriVent BioPharma, 

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days ArriVent BioPharma, Common has generated negative risk-adjusted returns adding no value to investors with long positions. Even with uncertain performance in the last few months, the Stock's fundamental drivers remain relatively invariable which may send shares a bit higher in October 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.
ScanTech AI Systems 

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days ScanTech AI Systems has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in October 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders.

ArriVent BioPharma, and ScanTech Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with ArriVent BioPharma, and ScanTech

The main advantage of trading using opposite ArriVent BioPharma, and ScanTech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if ArriVent BioPharma, position performs unexpectedly, ScanTech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ScanTech will offset losses from the drop in ScanTech's long position.
The idea behind ArriVent BioPharma, Common and ScanTech AI Systems pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Other Complementary Tools

Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format